
Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.
A Case of Advanced Serous Ovarian Cancer
Case: A 69-year-old Woman with Advanced Serous Ovarian Cancer
January 2017
April 2018






